Title21 Health Solutions Acquires MyCellHub
Scottsdale, AZ — January 6, 2026 · KMAK Capital
Title21 Health Solutions has acquired MyCellHub and its manufacturing execution system platform.
Per the announcement, the MES technology is designed for the healthcare, biotech, and cell therapy sectors, delivering real-time production monitoring, digital batch record management, and quality management embedded within manufacturing operations. With the addition, Title21 says it can serve as a single-source provider across standard of care hematopoietic cell transplant, advanced biotherapy manufacturing, integrated analytics, and quality management.
“This strategic addition to our expanding product portfolio positions Title21 as the leader in arm-to-arm workflow, documentation, and compliance solutions for the developers, manufacturers, and clinical providers of life-saving biotherapies.”
“We founded MyCellHub on the belief that GMP operations should be digital, efficient, and error-resistant. Title21 shares this vision.”
The acquisition extends Title21 from quality management into the manufacturing floor itself.